Multiple Sclerosis International最新文献_第5页

What Are the Participants' Perspectives of Taking Melatonin for the Treatment of Nocturia in Multiple Sclerosis? A Qualitative Study Embedded within a Double-Blind RCT. 参与者对服用褪黑素治疗多发性硬化夜尿症的看法是什么?一项双盲随机对照试验的定性研究。

IF 2.5

Multiple Sclerosis International Pub Date : 2018-10-18 eCollection Date: 2018-01-01 DOI: 10.1155/2018/4721505

Rafiyah Khan, Alan Uren, Luke Canham, David Cottrell, Marcus J Drake, Nikki Cotterill

{"title":"What Are the Participants' Perspectives of Taking Melatonin for the Treatment of Nocturia in Multiple Sclerosis? A Qualitative Study Embedded within a Double-Blind RCT.","authors":"Rafiyah Khan, Alan Uren, Luke Canham, David Cottrell, Marcus J Drake, Nikki Cotterill","doi":"10.1155/2018/4721505","DOIUrl":"https://doi.org/10.1155/2018/4721505","url":null,"abstract":"Background: Multiple Sclerosis (MS) is a chronic neurological disorder caused by neurodegeneration within the central nervous system. It results in impaired physical, cognitive, and psychological functioning and can also lead to lower urinary tract symptoms including nocturia. While clinical trials have suggested an association between nocturia and melatonin secretion, to our knowledge, no qualitative research has been conducted on the experience of taking melatonin to treat nocturia in progressive MS within a clinical trial.Methods: 17 semistructured qualitative interviews were conducted as part of a double-blind, randomised, placebo controlled, crossover, clinical trial with consenting adults with MS. Interviews explored participants' experiences of nocturia associated with MS and their experience of taking melatonin as a trial treatment for nocturia versus a placebo. Data was analysed using a thematic analysis.Results: Themes on the experience of nocturia revealed participants' understandings of nocturia, the impact it had on their night, and increased daily fatigue. Themes on the intervention showed perceived improvements to nocturia, sleep, and energy and negative effects including lethargy, a lack of significant change, and physical side effects including vivid dreams.Conclusion: This qualitative exploration revealed an association between nocturia and increased levels of fatigue during the day by those with MS. However, perspectives towards the effectiveness of melatonin as a potential treatment varied as both placebo and melatonin were perceived as having very similar effects.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2018 ","pages":"4721505"},"PeriodicalIF":2.5,"publicationDate":"2018-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/4721505","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36716729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The Role of Wearable Devices in Multiple Sclerosis. 可穿戴设备在多发性硬化症中的作用。

IF 2.5

Multiple Sclerosis International Pub Date : 2018-10-10 DOI: 10.1155/2018/7627643

Maddalena Sparaco, Luigi Lavorgna, Renata Conforti, Gioacchino Tedeschi, Simona Bonavita

{"title":"The Role of Wearable Devices in Multiple Sclerosis.","authors":"Maddalena Sparaco, Luigi Lavorgna, Renata Conforti, Gioacchino Tedeschi, Simona Bonavita","doi":"10.1155/2018/7627643","DOIUrl":"10.1155/2018/7627643","url":null,"abstract":"Multiple sclerosis (MS) is the most common neurological disorder in young adults. The prevalence of walking impairment in people with MS (pwMS) is estimated between 41% and 75%. To evaluate the walking capacity in pwMS, the patient reported outcomes (PROs) and performance-based tests (i.e., the 2-minute walk test, the 6-minute walk test, the Timed 25-Foot Walk Test, the Timed Up and Go Test, and the Six Spot Step Test) could be used. However, some studies point out that the results of both performance-based tests and objective measures (i.e., by accelerometer) could not reflect patient reports of walking performance and impact of MS on daily life. This review analyses different motion sensors embedded in smartphones and motion wearable device (MWD) that can be useful to measure free-living walking behavior, to evaluate falls, fatigue, sedentary lifestyle, exercise, and quality of sleep in everyday life of pwMS. Caveats and limitations of MWD such as variable accuracy, user adherence, power consumption and recharging, noise susceptibility, and data management are discussed as well.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2018 ","pages":"7627643"},"PeriodicalIF":2.5,"publicationDate":"2018-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/7627643","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36657906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 34

Estimating Everyday Neuropsychological Functioning in Multiple Sclerosis: Reliability and Validity of the Greek Multiple Sclerosis Neuropsychological Questionnaire. 估计多发性硬化症患者的日常神经心理功能:希腊多发性硬化症神经心理问卷的信度和效度。

IF 2.5

Multiple Sclerosis International Pub Date : 2018-09-25 eCollection Date: 2018-01-01 DOI: 10.1155/2018/6301535

Eleni Konstantinopoulou, Panagiotis Ioannidis, Christos Bakirtzis, Virginia Giantzi, Theodora Afrantou, Dimitrios Parissis, Lambros Messinis, Grigorios Nasios, Nikolaos Grigoriadis

{"title":"Estimating Everyday Neuropsychological Functioning in Multiple Sclerosis: Reliability and Validity of the Greek Multiple Sclerosis Neuropsychological Questionnaire.","authors":"Eleni Konstantinopoulou, Panagiotis Ioannidis, Christos Bakirtzis, Virginia Giantzi, Theodora Afrantou, Dimitrios Parissis, Lambros Messinis, Grigorios Nasios, Nikolaos Grigoriadis","doi":"10.1155/2018/6301535","DOIUrl":"https://doi.org/10.1155/2018/6301535","url":null,"abstract":"The Multiple Sclerosis Neuropsychological Questionnaire is a brief screening questionnaire for the assessment of everyday neuropsychological competence of patients with Multiple Sclerosis. The aim of the present study was to examine psychometric properties of the Greek version of the instrument. One hundred and three MS patients and 60 informants participated in the present study and completed the questionnaire. From the initial patient sample, 51 participants completed broadly used neuropsychological tests and measures estimating cognitive failures and depression. Moreover, after a six-month interval the MSNQ was administered to 58 patients from the initial sample in order to explore test-retest reliability. Cronbach's α was 0.92 and 0.93 for patient and informant forms, respectively. The patient form was correlated significantly with measures of cognitive failures and depression. Low correlations were found between the informant form and performance on cognitive tests. In regard to the patient form, significant correlation was observed between repeated administrations and, psychometrically, the three-factor structure was preferable than the one-factor structure. The present study confirms the already established pattern of correlations among the two MSNQ forms, neuropsychological test performance and depression measurements. Additional research is needed in order to define a cut-off score for the MSNQ-I providing further information about the diagnostic interpretability of the instrument.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2018 ","pages":"6301535"},"PeriodicalIF":2.5,"publicationDate":"2018-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/6301535","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36658775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Decision-Making in Multiple Sclerosis Patients: A Systematic Review. 多发性硬化症患者的决策:一项系统综述。

IF 2.5

Multiple Sclerosis International Pub Date : 2018-03-12 eCollection Date: 2018-01-01 DOI: 10.1155/2018/7835952

Mireille Neuhaus, Pasquale Calabrese, Jean-Marie Annoni

{"title":"Decision-Making in Multiple Sclerosis Patients: A Systematic Review.","authors":"Mireille Neuhaus, Pasquale Calabrese, Jean-Marie Annoni","doi":"10.1155/2018/7835952","DOIUrl":"https://doi.org/10.1155/2018/7835952","url":null,"abstract":"Background: Multiple sclerosis (MS) is frequently associated with cognitive and behavioural deficits. A growing number of studies suggest an impact of MS on decision-making abilities. The aim of this systematic review was to assess if (1) performance of MS patients in decision-making tasks was consistently different from controls and (2) whether this modification was associated with cognitive dysfunction and emotional alterations.Methods: The search was conducted on Pubmed/Medline database. 12 studies evaluating the difference between MS patients and healthy controls using validated decision-making tasks were included. Outcomes considered were quantitative (net scores) and qualitative measurements (deliberation time and learning from feedback).Results: Quantitative and qualitative decision-making impairment in MS was present in 64.7% of measurements. Patients were equally impaired in tasks for decision-making under risk and ambiguity. A correlation to other cognitive functions was present in 50% of cases, with the highest associations in the domains of processing speed and attentional capacity.Conclusions: In MS patients, qualitative and quantitative modifications may be present in any kind of decision-making task and can appear independently of other cognitive measures. Since decision-making abilities have a significant impact on everyday life, this cognitive aspect has an influential importance in various MS-related treatment settings.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2018 ","pages":"7835952"},"PeriodicalIF":2.5,"publicationDate":"2018-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/7835952","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36065096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka. 斯里兰卡多发性硬化症患者鞘内抗体反应明显低。

IF 2.5

Multiple Sclerosis International Pub Date : 2018-02-28 eCollection Date: 2018-01-01 DOI: 10.1155/2018/5342936

S M K Gamage, I Wijeweera, S B Adikari, Katharina Fink, Jan Hillert, Anna Fogdell-Hahn, H M A Sominanda

{"title":"Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka.","authors":"S M K Gamage, I Wijeweera, S B Adikari, Katharina Fink, Jan Hillert, Anna Fogdell-Hahn, H M A Sominanda","doi":"10.1155/2018/5342936","DOIUrl":"https://doi.org/10.1155/2018/5342936","url":null,"abstract":"Multiple sclerosis (MS) is a heterogeneous disease which is poorly studied in Asia, where the disease is known to be rare with significant differences in clinical and radiological presentations and intrathecal antibody response. Therefore the objective of this study was to determine clinical presentation, radiological and neurophysiological characteristics, and oligoclonal band status in Sri Lankan MS patients, following careful exclusion of patients with neuromyelitis optica spectrum disorders and other conditions mimicking multiple sclerosis. Sixty-nine MS patients were recruited to the study adhering to McDonald 2010 criteria. Their clinical presentation, characteristics of central nervous system lesions in magnetic resonance imaging, visual evoked potential (VEP) results, oligoclonal bands (OCB), and AQP4 antibody status were studied. Of 69 MS patients, 54%, 6%, and 1% were relapsing remitting, secondary progressive, and primary progressive, respectively, and 39% were patients with clinically isolated syndrome. The commonest clinical presentations were cerebral motor followed by cerebral sensory and optic neuritis. Majority had typical periventricular and infratentorial lesions in MRI. Though not clinically apparent, bilateral delay of P100 wave latency was present in 52%. OCB positivity was 42% and AQP4 antibody was positive in only one patient. In conclusion, this group of Sri Lankan MS patients shares most of the clinical and radiological features of Caucasian MS patients. However, the OCB positivity is lower in this group, when compared to the Caucasian MS populations.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2018 ","pages":"5342936"},"PeriodicalIF":2.5,"publicationDate":"2018-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/5342936","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36034293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

The Prevalence of Anti-Aquaporin 4 Antibody in Patients with Idiopathic Inflammatory Demyelinating Diseases Presented to a Tertiary Hospital in Malaysia: Presentation and Prognosis 抗水通道蛋白4抗体在马来西亚一家三级医院的特发性炎性脱髓鞘疾病患者中的流行:表现和预后

IF 2.5

Multiple Sclerosis International Pub Date : 2017-01-19 DOI: 10.1155/2017/1359761

S. Abdullah, W. Wong, C. Tan

{"title":"The Prevalence of Anti-Aquaporin 4 Antibody in Patients with Idiopathic Inflammatory Demyelinating Diseases Presented to a Tertiary Hospital in Malaysia: Presentation and Prognosis","authors":"S. Abdullah, W. Wong, C. Tan","doi":"10.1155/2017/1359761","DOIUrl":"https://doi.org/10.1155/2017/1359761","url":null,"abstract":"Background. There have been inconsistent reports on the prevalence and pathogenicity of anti-Aquaporin 4 (AQP4) in patients presented with idiopathic inflammatory demyelinating diseases (IIDDs). Objective. To estimate the prevalence of anti-AQP4 antibody in patients with IIDDs presented to University Malaya Medical Centre in terms of patients' clinical and radiological presentations and prognoses. Methods. Retrospective data review of IIDDs patients presented from 2005 to 2015. Patients were classified into classical multiple sclerosis (CMS), opticospinal (OS) presentation, optic neuritis (ON), transverse myelitis (TM), brainstem syndrome (BS), and tumefactive MS. Anti-Aquaporin 4 antibody was tested using the Indirect Immunofluorescence Test (IIFT) cell-based assay. Statistical analysis was done using the SPSS version 20. Results. Anti-AQP4 antibody was detected in 53% of patients presented with IIDDs. CMS was more common in the seronegative group, 27/47 (57.45%; p < 0.001). Conversely, OS involvement was more common in the seropositive group, 26/53 (49.06%; p < 0.001). Longitudinally extensive spinal cord lesions (LESCLs) on MRI were also more common in the seropositive group, 29/40 (72.50%; p = 0.004). Only 2/40 (5.00%) had MRI evidence of patchy or multiple short-segment spinal cord lesions in the AQP4-positive group (p = 0.003). The relapse rate and Expanded Disability Status Scale (EDSS) were also higher in the seropositive group (5.43 versus 3.17, p = 0.005; 4.07 versus 2.51, p = 0.006, resp.). Typical clinical presentations that defined NMO were also seen in the seronegative patients, but in a lower frequency. Conclusion. Our cohort of patients had a higher prevalence of seropositivity of anti-AQP4 antibody as compared to those in Western countries. This was also associated with a more typical presentation of opticospinal involvement with LESCLs on MRI, a higher rate of relapse, and EDSS.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2017 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2017-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/1359761","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43353621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Which Environmental Factor Is Correlated with Long-Term Multiple Sclerosis Incidence Trends: Ultraviolet B Radiation or Geomagnetic Disturbances? 哪种环境因素与多发性硬化症的长期发病趋势相关:紫外线B辐射还是地磁干扰?

IF 2.5

Multiple Sclerosis International Pub Date : 2017-01-01 Epub Date: 2017-10-24 DOI: 10.1155/2017/4960386

Seyed Aidin Sajedi, Fahimeh Abdollahi

{"title":"Which Environmental Factor Is Correlated with Long-Term Multiple Sclerosis Incidence Trends: Ultraviolet B Radiation or Geomagnetic Disturbances?","authors":"Seyed Aidin Sajedi, Fahimeh Abdollahi","doi":"10.1155/2017/4960386","DOIUrl":"https://doi.org/10.1155/2017/4960386","url":null,"abstract":"Background: Insufficient received ultraviolet B radiation (UV) is regarded as the main environmental risk factor (RF) for MS in vitamin D deficiency hypothesis. Nevertheless, geomagnetic disturbance (GMD) has also been proposed as a potential trigger for MS in GMD hypothesis. The aim of this study was to investigate which of these mentioned RF is correlated with long-term ultradecadal MS incidence.Methods: After a systematic search, long-term incidence reports of the United Kingdom (UK), Denmark, Tayside County, Nordland County, the Orkney, and Shetland Islands were selected for this retrospective time-series study. Possible lead-lag relationships between MS incidence, GMD, and UV were evaluated by cross-correlation analysis.Results: Significant positive correlations between GMD and MS incidence were seen in Tayside County (at lag of 2 years: rS = 0.38), Denmark (peak correlation at lag of 2 years: rS = 0.53), and UK (at lag of 1 year: rS = 0.50). We found a positive correlation between received UV and MS incidences in the Nordland at lag of 1 year (rS = 0.49).Conclusion: This study found significant positive correlations between alterations in GMD with alterations in long-term MS incidence in three out of six studied locations and supports the GMD hypothesis. The observed significant correlation between MS and UV is positive; hence it is not supportive for UV related vitamin D deficiency hypothesis.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2017 ","pages":"4960386"},"PeriodicalIF":2.5,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/4960386","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35219389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Dealing with Chronic Illness: Experiences of Iranian Families of Persons with Multiple Sclerosis-A Qualitative Study. 处理慢性疾病:伊朗多发性硬化症患者家庭的经验-定性研究。

IF 2.5

Multiple Sclerosis International Pub Date : 2017-01-01 Epub Date: 2017-09-07 DOI: 10.1155/2017/9243161

Hossein Ebrahimi, Hadi Hasankhani, Hossein Namdar, Esmail Khodadadi, Marjaneh Fooladi

{"title":"Dealing with Chronic Illness: Experiences of Iranian Families of Persons with Multiple Sclerosis-A Qualitative Study.","authors":"Hossein Ebrahimi, Hadi Hasankhani, Hossein Namdar, Esmail Khodadadi, Marjaneh Fooladi","doi":"10.1155/2017/9243161","DOIUrl":"https://doi.org/10.1155/2017/9243161","url":null,"abstract":"Background: Today family members are providing care and support to each other during illness. In particular, in chronic illness, such as multiple sclerosis, the families are more involved in caring for and supporting their patients, so they use several strategies to cope with this situation. The purpose of this study was to explore the coping strategies in family caregivers of persons with multiple sclerosis in Iran.Methods: This is a qualitative study that was conducted through 18 family caregivers of persons with multiple sclerosis. A purposeful sampling method was used. Data were collected through semistructured and in-depth interviews conducted in Multiple Sclerosis Society and hospitals of Tabriz in Iran. The collected data was analyzed according to qualitative content analysis.Results: Five main categories were elicited from interviews: \"using spirituality,\" \"living with hope,\" \"experiencing persistence and stability,\" \"seeking support,\" and \"seeking alternative treatments.\" Conclusion. The study findings can help to inform the support given to families to help them cope with the effects of caring for someone with multiple sclerosis. Health system managers and professionals by using these results are able to support patients and their families appropriately in order to improve their quality of life and alleviate the complications of disease.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2017 ","pages":"9243161"},"PeriodicalIF":2.5,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/9243161","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35503490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives. 预测多发性硬化症治疗反应的药物基因生物标志物：当前和未来展望。

IF 2.5

Multiple Sclerosis International Pub Date : 2017-01-01 Epub Date: 2017-07-19 DOI: 10.1155/2017/6198530

Patricia K Coyle

{"title":"Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives.","authors":"Patricia K Coyle","doi":"10.1155/2017/6198530","DOIUrl":"10.1155/2017/6198530","url":null,"abstract":"Disease-modifying therapies (DMTs) have significantly advanced the treatment of relapsing multiple sclerosis (MS), decreasing the frequency of relapses, disability, and magnetic resonance imaging lesion formation. However, patients' responses to and tolerability of DMTs vary considerably, creating an unmet need for biomarkers to identify likely responders and/or those who may have treatment-limiting adverse reactions. Most studies in MS have focused on the identification of pharmacogenetic markers, using either the candidate-gene approach, which requires prior knowledge of the genetic marker and its role in the target disease, or genome-wide association, which examines multiple genetic variants, typically single nucleotide polymorphisms (SNPs). Both approaches have implicated numerous alleles and SNPs in response to selected MS DMTs. None have been validated for use in clinical practice. This review covers pharmacogenetic markers in clinical practice in other diseases and then reviews the current status of MS DMT markers (interferon β, glatiramer acetate, and mitoxantrone). For a complex disease such as MS, multiple biomarkers may need to be evaluated simultaneously to identify potential responders. Efforts to identify relevant biomarkers are underway and will need to be expanded to all MS DMTs. These will require extensive validation in large patient groups before they can be used in clinical practice.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2017 ","pages":"6198530"},"PeriodicalIF":2.5,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35265182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effects of Aerobic Exercise on the Recovery of Walking Ability and Neuroplasticity in People with Multiple Sclerosis: A Systematic Review of Animal and Clinical Studies. 有氧运动对多发性硬化症患者行走能力恢复和神经可塑性的影响：动物和临床研究的系统回顾

IF 2.5

Multiple Sclerosis International Pub Date : 2017-01-01 Epub Date: 2017-10-17 DOI: 10.1155/2017/4815958

Augustine Joshua Devasahayam, Matthew Bruce Downer, Michelle Ploughman

{"title":"The Effects of Aerobic Exercise on the Recovery of Walking Ability and Neuroplasticity in People with Multiple Sclerosis: A Systematic Review of Animal and Clinical Studies.","authors":"Augustine Joshua Devasahayam, Matthew Bruce Downer, Michelle Ploughman","doi":"10.1155/2017/4815958","DOIUrl":"10.1155/2017/4815958","url":null,"abstract":"Introduction: Walking is of high priority for people with multiple sclerosis (PwMS). It remains unclear whether aerobic exercise can improve walking ability and upregulate neurotrophins. This review aims to consolidate evidence to develop optimal aerobic training parameters to enhance walking outcomes and neuroplasticity in PwMS.Methods: Clinical studies examining aerobic exercise for ≥3 weeks, having outcomes on walking with or without neurotrophic markers, were included. Studies utilizing animal models of MS were included if they employed aerobic exercise with outcomes on neurological recovery and neurotrophins. From a total of 1783 articles, 12 clinical and 5 animal studies were included.Results: Eleven clinical studies reported improvements in walking ability. Only two clinical studies evaluated both walking and neurotrophins, and neither found an increase in neurotrophins despite improvements in walking. Patients with significant walking impairments were underrepresented. Long-term follow-up revealed mixed results. Two animal studies reported a positive change in both neurological recovery and neurotrophins.Conclusion: Aerobic exercise improves walking ability in PwMS. Gains are not consistently maintained at 2- to 9-month follow-up. Studies examining levels of neurotrophins are inconclusive, necessitating further research. Aerobic exercise enhances both neurological recovery and neurotrophins in animal studies when started 2 weeks before induction of MS.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2017 ","pages":"4815958"},"PeriodicalIF":2.5,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35643799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0